MEIP Logo

MEI Pharma, Inc. (MEIP) 

NASDAQ
Market Cap
$19.06M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
96 of 809
Rank in Industry
72 of 445

Largest Insider Buys in Sector

MEIP Stock Price History Chart

MEIP Stock Performance

About MEI Pharma, Inc.

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

Insider Activity of MEI Pharma, Inc.

Over the last 12 months, insiders at MEI Pharma, Inc. have bought $2.11M and sold $0 worth of MEI Pharma, Inc. stock.

On average, over the past 5 years, insiders at MEI Pharma, Inc. have bought $774,336 and sold $100,625 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Anson Funds Management LP (10 percent owner) — $1.27M. Funicular Funds, LP (10 percent owner) — $845,038.

The last purchase of 48,060 shares for transaction amount of $329,331 was made by Anson Funds Management LP (10 percent owner) on 2023‑09‑22.

List of Insider Buy and Sell Transactions, MEI Pharma, Inc.

2023-09-22PurchaseAnson Funds Management LP10 percent owner
48,060
0.6547%
$6.85$329,331-39.87%
2023-09-22PurchaseFunicular Funds, LP10 percent owner
32,040
0.4364%
$6.85$219,554-39.87%
2023-09-21PurchaseAnson Funds Management LP10 percent owner
33,600
0.4922%
$6.46$217,110-31.19%
2023-09-21PurchaseFunicular Funds, LP10 percent owner
22,400
0.3281%
$6.46$144,740-31.19%
2023-09-20PurchaseAnson Funds Management LP10 percent owner
120,000
1.7317%
$6.01$721,116-26.88%
2023-09-20PurchaseFunicular Funds, LP10 percent owner
80,000
1.1544%
$6.01$480,744-26.88%
2023-02-28PurchaseBaltic Charles V. IIIdirector
81,500
0.0619%
$0.23$18,338+44.66%
2021-02-23SaleDRISCOLL FREDERICK Wdirector
25,000
0.0011%
$4.03$100,625-29.32%
2019-12-19PurchaseGOLD DANIEL P PHDChief Executive Officer
18,750
0.0011%
$1.60$30,000+54.44%
2019-12-19PurchaseDRISCOLL FREDERICK Wdirector
62,500
0.0035%
$1.60$100,000+54.44%
2019-12-19PurchaseDrazba Brian G.Chief Financial Officer
12,500
0.0007%
$1.60$20,000+54.44%
2019-12-19PurchaseReynolds Thomas Cdirector
10,000
0.0006%
$1.60$16,000+54.44%
2019-09-06PurchaseWhite Christine Annadirector
15,000
0.001%
$1.74$26,075+32.37%
2018-08-07SaleUrso David MChief Operating Officer & GC
9,500
0.0007%
$3.58$34,044-17.86%
2017-11-27SaleBaltic Charles V. IIIdirector
11,000
0.0015%
$2.21$24,272+38.56%
2017-11-27PurchaseBaltic Charles V. IIIdirector
11,000
0.0015%
$2.25$24,801+38.56%
2015-11-09SaleVIVO VENTURES VII, LLC10 percent owner
314,704
0.0465%
$1.75$550,732-15.70%
2015-11-09SaleVivo Ventures V, LLC10 percent owner
18,284
0.0027%
$1.75$31,997-15.70%
2015-11-06SaleVIVO VENTURES VII, LLC10 percent owner
15,120
0.0023%
$1.85$27,972-19.55%
2015-11-06SaleVivo Ventures V, LLC10 percent owner
880
0.0001%
$1.85$1,628-19.55%

Insider Historical Profitability

39.57%
Anson Funds Management LP10 percent owner
864188
12.9702%
$2.8630
Funicular Funds, LP10 percent owner
460840
6.9165%
$2.8630
NOVOGEN LTD10 percent owner
52408295
786.5736%
$2.8610
VIVO VENTURES VII, LLC10 percent owner
3163105
47.4737%
$2.86011
GOLD DANIEL P PHDChief Executive Officer
361632
5.4276%
$2.8610+54.44%
Vivo Ventures V, LLC10 percent owner
183767
2.7581%
$2.86011
Baltic Charles V. IIIdirector
105750
1.5872%
$2.86101+30.85%
Drazba Brian G.Chief Financial Officer
37500
0.5628%
$2.8610+54.44%
DRISCOLL FREDERICK Wdirector
37500
0.5628%
$2.8611+54.44%
Urso David MChief Operating Officer & GC
24106
0.3618%
$2.8601
Rueckert William Dodgedirector
20849
0.3129%
$2.8641
White Christine Annadirector
15000
0.2251%
$2.8610+32.37%
JOHNSTON PHILIP Adirector
10000
0.1501%
$2.8610
Reynolds Thomas Cdirector
10000
0.1501%
$2.8610+54.44%
SEATON DAVID RCFO & Secretary
5000
0.075%
$2.8610
Williams Bryandirector
5000
0.075%
$2.8610
NAUGHTON CHRISTOPHERCEO & President
5000
0.075%
$2.8620
New Leaf Ventures II, L.P.10 percent owner
0
0%
$2.86010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Anson Funds Management Lp$4.37M16.411.09M0%+$00.2
The Vanguard Group$1.56M5.85389,8070%+$0<0.0001
Acadian Asset Management$845,000.003.18211,733-6.06%-$54,507.38<0.01
Renaissance Technologies$572,000.002.15143,092-5.17%-$31,179.94<0.01
BlackRock$330,464.001.2482,616-0.84%-$2,808.00<0.0001
Susquehanna International Group$286,360.001.0771,590+431.91%+$232,524.00<0.0001
Carlson Capital, L.P.$256,000.000.9664,000-13.51%-$40,000.000.03
Geode Capital Management$209,783.000.7952,431+1.58%+$3,260.92<0.0001
Macquarie Group$120,000.000.4529,9990%+$0<0.0001
Bridgeway Capital Management$107,476.000.426,8690%+$0<0.01
Northern Trust$92,224.000.3523,056-6.96%-$6,896.00<0.0001
National Bank Of Canada Fi$69,230.000.3523,000+283.33%+$51,170.00<0.0001
State Street$71,284.000.2717,8210%+$0<0.0001
Dimensional Fund Advisors$67,848.000.2616,962+54.96%+$24,064.00<0.0001
Morgan Stanley$23,472.000.095,8680%+$0<0.0001
UBS$17,192.000.074,298+632.2%+$14,844.00<0.0001
Group One Trading$14,536.000.063,634-35.77%-$8,096.00<0.0001
Simplex Trading Llc$11,000.000.042,868New+$11,000.00<0.0001
Newbridge Financial Services Group Inc$7,996.000.031,9990%+$0<0.01
Tower Research Capital$7,724.000.031,931+45.52%+$2,416.00<0.0001
Citadel Advisors LLC$2,760.000.01690New+$2,760.00<0.0001
Bank of America$2,568.000.01642-0.62%-$16.00<0.0001
Evermay Wealth Management, LLC$504.00<0.01126New+$504.00<0.0001
Wells Fargo$576.00<0.011440%+$0<0.0001
RhumbLine Advisers$488.00<0.011220%+$0<0.0001
Advisor Group Holdings Inc$400.00<0.011000%+$0<0.0001
JPMorgan Chase$228.00<0.0157+7.55%+$16.00<0.0001
Royal Bank of Canada$0<0.0172-99.39%-$0<0.0001
Qube Research & Technologies$8.00<0.0120%+$0<0.0001
CWM LLC$0<0.0110%+$0<0.0001